Download PDF
Homœopathic Links
DOI: 10.1055/s-0042-1755539
Case Report

Homoeopathic Management of Duchenne Muscular Dystrophy: A Case Report

Sanjib Sahoo
1   Department of Homoeopathic Materia Medica, National Institute of Homoeopathy, Kolkata, West Bengal, India
,
Soumya Bhattacharya
2   Department of Homoeopathic Pharmacy, National Institute of Homoeopathy, Kolkata, West Bengal, India
,
Abhijit Dutta 
3   Maynaguri Rural Hospital, Jalpaiguri, West Bengal, under Department of Health & Family Welfare, Govt. of West Bengal, India
4   Department of Organon of Medicine & Homoeopathic Philosophy, National Institute of Homoeopathy, Kolkata, West Bengal, India
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Background Duchenne muscular dystrophy (DMD) is a hereditary disorder having a significant socioeconomic burden. Primary abnormality may be in muscle membrane, due to the alterations of dystrophin protein. The patient usually has trouble in muscular activities like running, climbing staircases, jumping, getting up from the ground, suffers from frequent falls and gait abnormality. Owing to the limited therapeutic modality for DMD in conventional medicine, an alternative approach is warranted.

Case Report An 8-year-old male child presented with unsteady gait, frequent falls, polymyalgia and weakness of limbs. Based on the clinical presentation and laboratory investigations, we diagnosed the case as DMD. On laboratory investigation, the serum creatine phosphokinase (CPK) level was significantly raised. After a thorough clinical evaluation, he was treated with Radium bromide, Veratrum viride and Calcarea phosphorica at different time points. Clinically, the improvement was marked in regard to symptomatology and reduced serum CPK level.

Conclusion This is the first case demonstrating a favourable therapeutic course of homoeopathic treatment in DMD. For any further conclusion regarding the causal attribution, an individualistic n-of-1 trial may be warranted.

Keywords

Duchenne muscular dystrophy - homoeopathy - case report - n-of-1 trial

Consent

The study was verbally explained to the patient, and written consent was obtained. However, the patient was free to withdraw from the study at any time.




Publication History

Article published online:
08 September 2022

© 2022. Thieme. All rights reserved.

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers 2021; 7 (01) 13 DOI: 10.1038/s41572-021-00248-3.
    CrossrefPubMedGoogle Scholar
  • 2 Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health 2015; 51 (08) 759-764
    CrossrefPubMedGoogle Scholar
  • 3 Birnkrant DJ, Bushby K, Bann CM. et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018; 17 (03) 251-267
    CrossrefPubMedGoogle Scholar
  • 4 Ryder S, Leadley RM, Armstrong N. et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis 2017; 12 (01) 79
    CrossrefPubMedGoogle Scholar
  • 5 Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 2020; 15 (01) 141 DOI: 10.1186/s13023-020-01430-8.
    CrossrefPubMedGoogle Scholar
  • 6 Roberts HA. The Principles and Art of Cure by Homoeopathy: A Modern Textbook. B. Jain Publishers; 2016
    Google Scholar
  • 7 Mathie RT, Lloyd SM, Legg LA. et al. Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis. Syst Rev 2014; 3 (01) 142
    CrossrefPubMedGoogle Scholar
  • 8 Boericke W. Pocket Manual of Homoeopathic Materia Medica & Repertory: Comprising of the Characteristic and Guiding Symptoms of All Remedies (clinical and Pahtogenetic [sic]) Including Indian Drugs. New Delhi: B. Jain Publishers; 2002
    Google Scholar
  • 9 Thada PK, Bhandari J, Umapathi KK. Becker Muscular Dystrophy. [Updated 2021 Oct 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Jan-. Accessed July 30, 2022, at: https://www.ncbi.nlm.nih.gov/books/NBK556092/
    Google Scholar
  • 10 Bonne G, Leturcq F, Ben Yaou R. Emery-Dreifuss Muscular Dystrophy. 2004 Sep 29 [Updated 2019 Aug 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. Accessed July 30, 2022, at: https://www.ncbi.nlm.nih.gov/books/NBK1436/
    Google Scholar
  • 11 Angelini C. LGMD. Identification, description and classification. Acta Myol 2020; 39 (04) 207-217
    PubMedGoogle Scholar
  • 12 Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 Feb 24 [Updated 2020 Dec 3]. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. Accessed July 30, 2022, at: https://www.ncbi.nlm.nih.gov/books/NBK1352/
    Google Scholar
  • 13 Adler UC, Adler MS. Hahnemann's experiments with 50 millesimal potencies: a further review of his casebooks. Homeopathy 2006; 95 (03) 171-181
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Ferlini A, Flanigan KM, Lochmuller H, Muntoni F, 't Hoen PA, McNally E. 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands. Neuromuscul Disord 2015; 25 (02) 184-198
    CrossrefPubMedGoogle Scholar
  • 15 Saha S, Joardar A, Roy S. et al. Serum creatine kinase and other profile of Duchenne muscular dystrophy and Becker muscular dystrophy: a cross-sectional survey in a tertiary care institution at Kolkata. CHRISMED J Health Res 2021; 8: 175-181
    PubMedGoogle Scholar